Education
About Us
Working with TipRanks
Follow Us
verbio Vereinigte BioEnergie AG (DE:VBK)
XETRA:VBK
Top Page
verbio Vereinigte BioEnergie
(XETRA:VBK)
Select Model
Select Model
Rating:58Neutral
Price Target:
€20.50
▼(-7.82% Downside)
The overall stock score reflects significant financial challenges, despite strong technical indicators. The earnings call provided some positive insights, but the company's valuation and financial performance remain concerning.
Positive Factors
Production Efficiency
High production efficiency in biodiesel indicates strong operational capabilities, enhancing the company's competitive position and profitability.
Revenue Growth
Significant growth in ethanol and biomethane production supports revenue expansion and strengthens market presence in renewable energy.
EBITDA Improvement
Improved EBITDA reflects enhanced financial performance, indicating better cost management and increased profitability potential.
Negative Factors
Rising Net Debt
Increased net debt may limit financial flexibility and strain cash flow, posing risks to long-term financial health and strategic initiatives.
Bioethanol Segment Loss
Continued losses in the Bioethanol segment highlight operational challenges, potentially affecting overall profitability and resource allocation.
Regulatory Uncertainty
Regulatory uncertainties, such as delays in RED III adoption, could impact future operations and strategic planning in the renewable energy sector.
verbio Vereinigte BioEnergie (VBK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.40B
Dividend Yield1.02%
Average Volume (3M)165.84K
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue Growth8.65%
EPS Growth-379.83%
CountryDE
Employees1,521
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.06
Shares Outstanding63,715,480
10 Day Avg. Volume196,028
30 Day Avg. Volume165,844
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.04
Price to Sales (P/S)0.49
P/FCF Ratio-6.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.50Price Target Upside-30.31% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
verbio Vereinigte BioEnergie Business Overview & Revenue Model
Company DescriptionVERBIO Vereinigte BioEnergie AG produces and supplies biofuels in Germany and rest of Europe. The company's products include biodiesel, bioethanol, biomethane, biosterol, bioglycerin, and liquid fertilizers. The company offers its products to oil corporations, oil traders, independent filling stations, haulage companies, public utilities, and vehicle fleets. VERBIO Vereinigte BioEnergie AG was founded in 2006 and is headquartered in Leipzig, Germany.
How the Company Makes MoneyVBK generates revenue primarily through the sale of renewable energy products, including biodiesel and biomethane, which are sold to various industries and consumers. The company benefits from government subsidies and incentives aimed at promoting renewable energy use, which enhances its profitability. Additionally, VBK has established key partnerships with agricultural producers for the sourcing of raw materials, such as organic waste and crops, which further supports its production processes. The diversification of its biofuel offerings and investment in advanced technologies also contribute to its revenue streams, positioning VBK as a competitive player in the bioenergy market.
verbio Vereinigte BioEnergie Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q1-2026)
| % Change Since: |
Next Earnings Date:Feb 12, 2026
Earnings Call Sentiment Neutral
The earnings call presented strong production and financial performance in key segments, particularly in biodiesel and biomethane. The company showed significant EBITDA improvement and positive developments in North America. However, challenges remain with increased net debt and losses in the Bioethanol segment. Uncertainties around regulatory impacts and technical issues during the call were also highlighted.Q1-2026 Updates
Positive Updates
Record Biodiesel Production
Biodiesel production reached close to 167,000 tonnes with a capacity utilization rate of 94%.
Ethanol and Biomethane Production Growth
Ethanol production increased by 10% year-on-year to 154,000 tonnes, while biomethane production grew by 24% year-on-year.
Significant EBITDA Improvement
EBITDA increased to EUR 15.4 million from minus EUR 6.6 million year-on-year.
Positive Developments in North America
The North American business contributed positively, with improved utilization at Nevada and efficiency gains in South Bend.
Strong Market Performance
Verbio achieved a greater premium versus the market in Q1 '25, '26, supported by co-product revenues and favorable commodity and ForEx developments.
Negative Updates
Increased Net Debt
Net debt increased due to negative free cash flow from reduced operating cash flow and strategic investments totaling around EUR 20 million.
Bioethanol Segment Loss
Although losses were cut by more than half, the Bioethanol and Biomethane segment reported a loss of minus EUR 9.5 million.
Technical Issues and Delays
Technical issues during the call and delays in the adoption of the RED III draft in Germany were noted.
Company Guidance
In the earnings call for the first quarter of fiscal year 2025-26, Verbio reported a record biodiesel production of approximately 167,000 tonnes with a capacity utilization rate near 94%. Ethanol production increased by 10% year-on-year to 154,000 tonnes, driven by efficiency gains. Biomethane production also grew by 24% year-on-year. The company achieved an EBITDA of EUR 15.4 million, up from a negative EUR 6.6 million, thanks to higher coproduct revenues and favorable commodity and currency developments. Despite an increase in net debt due to strategic investments totaling around EUR 20 million, Verbio maintained a stable equity ratio of 58%. The guidance remains unchanged, with expected EBITDA in the high double-digit million range for the fiscal year. The company is closely monitoring market developments, including the RED III transposition in Europe, which could influence future performance.verbio Vereinigte BioEnergie Financial Statement Overview
Summary
The company faces significant financial challenges, with declining profitability and negative margins. The balance sheet shows moderate leverage but poor returns on equity, and cash flow analysis reveals liquidity concerns with negative free cash flow growth.Income Statement
The income statement shows a concerning trend with declining profitability. The TTM data reveals a negative net profit margin of -8.74% and a negative EBIT margin of -7.41%, indicating operational challenges. Revenue growth is modest at 5.08%, but the company has struggled to maintain profitability, as seen in the negative EBITDA margin of 0.97%. Historically, the company had stronger margins, but recent performance has deteriorated significantly.Balance Sheet
The balance sheet reflects moderate leverage with a debt-to-equity ratio of 0.36, which is manageable. However, the return on equity is negative at -16.23% in the TTM, highlighting inefficiencies in generating returns for shareholders. The equity ratio is stable, suggesting a reasonable level of financial stability, but the declining ROE is a concern.Cash Flow
Cash flow analysis indicates significant challenges, with negative free cash flow growth and a free cash flow to net income ratio of -8.55 in the TTM. Operating cash flow is positive but insufficient to cover net income, as shown by the low operating cash flow coverage ratio of 0.045. The company's cash flow position has weakened, raising concerns about liquidity and financial flexibility.| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.66B | 1.58B | 1.67B | 1.97B | 1.81B | 1.03B |
| Gross Profit | 107.69M | 37.12M | 292.45M | 381.91M | 626.92M | 271.64M |
| EBITDA | 37.49M | -54.41M | 122.92M | 242.68M | 494.81M | 166.48M |
| Net Income | -119.11M | -138.01M | 19.96M | 132.02M | 315.63M | 93.20M |
Balance Sheet | ||||||
| Total Assets | 1.28B | 1.28B | 1.38B | 1.30B | 1.13B | 678.62M |
| Cash, Cash Equivalents and Short-Term Investments | 72.35M | 64.41M | 126.70M | 170.31M | 300.50M | 105.34M |
| Total Debt | 296.94M | 268.86M | 194.20M | 189.97M | 49.39M | 46.48M |
| Total Liabilities | 540.23M | 536.78M | 449.54M | 385.36M | 310.16M | 168.75M |
| Stockholders Equity | 743.18M | 746.29M | 925.67M | 909.47M | 816.23M | 507.85M |
Cash Flow | ||||||
| Free Cash Flow | -117.03M | -117.96M | -54.38M | -177.12M | 210.15M | 49.90M |
| Operating Cash Flow | 2.69M | 13.88M | 116.78M | 26.09M | 325.03M | 117.18M |
| Investing Cash Flow | -108.25M | -120.06M | -144.90M | -266.43M | -113.62M | -46.56M |
| Financing Cash Flow | 61.59M | 49.88M | -19.53M | 112.21M | -18.48M | -18.76M |
verbio Vereinigte BioEnergie Technical Analysis
Positive
22.24
Price Trends
18.33
Positive
15.03
Positive
12.74
Positive
Market Momentum
1.35
Negative
61.52
Neutral
72.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:VBK, the sentiment is Positive. The current price of 22.24 is above the 20-day moving average (MA) of 20.35, above the 50-day MA of 18.33, and above the 200-day MA of 12.74, indicating a bullish trend. The MACD of 1.35 indicates Negative momentum. The RSI at 61.52 is Neutral, neither overbought nor oversold. The STOCH value of 72.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:VBK.
verbio Vereinigte BioEnergie Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | €1.70B | 29.16 | 29.12% | 1.24% | 1.03% | 25.48% | |
62 Neutral | €3.51B | 14.58 | ― | 3.75% | -10.63% | -23.15% | |
58 Neutral | €1.40B | -11.71 | -14.66% | 1.02% | 8.65% | -379.83% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | €6.17B | 64.93 | 1.08% | 8.92% | -5.92% | -58.33% | |
46 Neutral | €1.54B | -6.35 | -5.69% | 0.59% | -6.82% | 71.94% |
* General Sector Average
DE:VBK
verbio Vereinigte BioEnergie
21.90
11.57
112.00%
DE:EVK
Evonik
13.24
-2.36
-15.13%
DE:LXS
LANXESS
17.86
-4.52
-20.21%
DE:WCH
Wacker Chemie AG
70.75
10.53
17.48%
DE:ACT
AlzChem Group AG
166.60
103.69
164.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.